Analyst Activity – FinnCap Reiterates Corporate on Avacta Group Plc (LON:AVCT)

Analyst Ratings For Avacta Group Plc (LON:AVCT)

Story continues below

Today, FinnCap reiterated its Corporate rating on Avacta Group Plc (LON:AVCT) with a price target of GBX 200.

There are 1 buy rating on the stock.

The current consensus rating on Avacta Group Plc (LON:AVCT) is Buy (Score: 3.00) with a consensus target price of GBX 200 per share, a potential .

Some recent analyst ratings include

  • 2/24/2017-FinnCap Reiterated Rating of Corporate.
  • 8/1/2016-Numis Securities Ltd Reiterated Rating of Buy.

    About Avacta Group Plc (LON:AVCT)
    Avacta Group plc is a biotechnology company. The Company is a developer of Affimer bio therapeutics and research reagents. Its segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. Its in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development.

    Recent Trading Activity for Avacta Group Plc (LON:AVCT)
    Shares of Avacta Group Plc closed the previous trading session at 66.75 down -0.75 -1.11% with 0 shares trading hands.

    An ad to help with our costs